Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 3213879b-dd88-413b-9910-8fd422c99805

Komzifti

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2025-12-09
Captured
2026-09-09T23:37:42.544548+00:00
Current indication reconciliation
Not reconciled
Boxed warning in this label
  1. WARNING: DIFFERENTIATION SYNDROME Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury, and rashes. If differentiation syndrome is suspected, interrupt KOMZIFTI and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement [see Dosage and Administration ( 2.5 ), Warnings and Precautions ( 5.1 ), and Adverse Reactions ( 6.1 )] . WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. If differentiation syndrome is suspected, interrupt KOMZIFTI and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement. ( 2.5 , 5.1 , 6.1 )

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 )
Full extracted label fields
application numbers
  1. NDA220305
boxed warning exact
  1. WARNING: DIFFERENTIATION SYNDROME Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury, and rashes. If differentiation syndrome is suspected, interrupt KOMZIFTI and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement [see Dosage and Administration ( 2.5 ), Warnings and Precautions ( 5.1 ), and Adverse Reactions ( 6.1 )] . WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. If differentiation syndrome is suspected, interrupt KOMZIFTI and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement. ( 2.5 , 5.1 , 6.1 )
brand names
  1. Komzifti
current indication status
not_reconciled
dailymed set url
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b650f696-3391-4274-8b55-a5f5e9d04769
generic names
  1. ZIFTOMENIB
id
3213879b-dd88-413b-9910-8fd422c99805
indications and usage exact
  1. 1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 )
indications and usage tables exact
    is original packager
    1. true
    manufacturer names
    1. Kura Oncology, Inc.
    matched search terms
    1. leukemia
    package ndcs
    1. 84696-200-90
    product ndcs
    1. 84696-200
    product types
    1. HUMAN PRESCRIPTION DRUG
    recent major changes exact
      record type
      complete_spl_indications_section_candidate
      routes
      1. ORAL
      rxcuis
      1. 2725990
      2. 2725996
      source batch
      file
      /private/tmp/cancer-full-research/indications/raw/labels-00100.json
      meta
      disclaimer
      Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
      last updated
      2026-09-09
      results
      limit
      100
      skip
      100
      total
      830
      sha256
      fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
      url
      https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=100&sort=id%3Aasc
      source url
      https://api.fda.gov/drug/label.json?search=id%3A%223213879b-dd88-413b-9910-8fd422c99805%22
      spl effective date
      2025-12-09
      spl effective time
      20251209
      spl set id
      b650f696-3391-4274-8b55-a5f5e9d04769
      spl version
      1
      substance names
      1. ZIFTOMENIB
      uniis
      1. 4MOD1F4ENC
      verification flags
      1. oncology_keyword_candidate_not_clinically_classified
      2. spl_text_not_verified_identical_to_latest_approved_label
      3. individual_indications_not_split_or_reconciled
      4. fda_label_posted_after_spl_effective_date_requires_version_review
      Drugs@FDA application source records
      1. application number
        NDA220305
        payload
        all indexed label documents
        1. Appl No
          220305
          Application Docs Date
          2025-12-15 00:00:00
          Application Docs ID
          84423
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          1
          Submission Type
          ORIG
        all submission records
        1. Appl No
          220305
          Review Priority
          PRIORITY
          Submission Class Code ID
          7
          Submission No
          1
          Submission Status
          AP
          Submission Status Date
          2025-11-13 00:00:00
          Submission Type
          ORIG
          Submissions Public Notes
        application number
        NDA220305
        approval interpretation
        Application linkage and approved submission are not indication-level current approval verification
        current indication status
        not_reconciled
        has approved submission record
        true
        latest approved submission date
        2025-11-13
        latest label selection rule
        max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
        latest posted label documents
        1. Appl No
          220305
          Application Docs Date
          2025-12-15 00:00:00
          Application Docs ID
          84423
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          1
          Submission Type
          ORIG
        official application record
        Appl No
        220305
        Appl Public Notes
        Appl Type
        NDA
        Sponsor Name
        KURA
        openfda application present
        true
        products
        1. Active Ingredient
          ZIFTOMENIB
          Appl No
          220305
          Drug Name
          KOMZIFTI
          Form
          CAPSULE;ORAL
          Product No
          001
          Reference Drug
          1
          Reference Standard
          1
          Strength
          200MG
          marketing status
          1. Prescription

      Source passages and status connections

      Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

      Passage 1 · positive indication candidate
      application numbers
      1. NDA220305
      brand names
      1. Komzifti
      classification reasons
      1. explicit_positive_indication_predicate
      2. tumor_or_malignant_hematology_words_in_positive_statement
      clinical review status
      pending
      content role
      positive_indication_candidate
      context span
      end
      549
      end exclusive
      true
      exact text
      1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no s
      label id
      3213879b-dd88-413b-9910-8fd422c99805
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
      start
      0
      current approval status
      not_reconciled
      duplicate text group
      dup-0d515fc0fca252947fd5
      extraction review status
      automated_candidate_pending_source_review
      generic names
      1. ZIFTOMENIB
      id
      ind-span-cd318739f8c70920eca2
      label id
      3213879b-dd88-413b-9910-8fd422c99805
      positive predicate support span
      end
      45
      end exclusive
      true
      exact text
      is indicated
      label id
      3213879b-dd88-413b-9910-8fd422c99805
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
      start
      33
      qualifier mentions
      1. context exact
        ATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) wi
        kind
        age
        polarity
        not_inferred
        span
        end
        81
        end exclusive
        true
        exact text
        adult patients
        label id
        3213879b-dd88-413b-9910-8fd422c99805
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
        start
        67
      2. context exact
        myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration (
        kind
        biomarker
        polarity
        not_inferred
        span
        end
        220
        end exclusive
        true
        exact text
        NPM1 ) mutation who have no satisfactory alt
        label id
        3213879b-dd88-413b-9910-8fd422c99805
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
        start
        176
      3. context exact
        ZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutatio
        kind
        stage_or_setting
        polarity
        not_inferred
        span
        end
        130
        end exclusive
        true
        exact text
        relapsed or refractory acute myeloid leukem
        label id
        3213879b-dd88-413b-9910-8fd422c99805
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
        start
        87
      4. context exact
        th a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies (
        kind
        prior_therapy_or_line
        polarity
        not_inferred
        span
        end
        281
        end exclusive
        true
        exact text
        no satisfactory alternative treatment options [see Dosage and Administration ( 2
        label id
        3213879b-dd88-413b-9910-8fd422c99805
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
        start
        201
      regulatory links
        schema version
        0.1.0
        source batch sha256
        fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
        source defined aliases
          source span
          end
          349
          end exclusive
          true
          exact text
          1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] .
          label id
          3213879b-dd88-413b-9910-8fd422c99805
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
          start
          0
          source url
          https://api.fda.gov/drug/label.json?search=id%3A%223213879b-dd88-413b-9910-8fd422c99805%22
          spl effective date
          2025-12-09
          spl set id
          b650f696-3391-4274-8b55-a5f5e9d04769
          spl version
          1
          structured fields status
          not_extracted_no_values_inferred_from_mentions
          structured indication
          age
          Source null
          approval pathway
          Source null
          biomarker and test
          Source null
          disease stage
          Source null
          limitations
          Source null
          line
          Source null
          prior therapy
          Source null
          regimen
          Source null
          tumor histology
          Source null
          use intent
          tumor_directed_candidate
          Passage 2 · positive indication candidate
          application numbers
          1. NDA220305
          brand names
          1. Komzifti
          classification reasons
          1. explicit_positive_indication_predicate
          2. tumor_or_malignant_hematology_words_in_positive_statement
          clinical review status
          pending
          content role
          positive_indication_candidate
          context span
          end
          597
          end exclusive
          true
          exact text
          eptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 )
          label id
          3213879b-dd88-413b-9910-8fd422c99805
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
          start
          150
          current approval status
          not_reconciled
          duplicate text group
          dup-10cc7422b44cd5c1e4c6
          extraction review status
          automated_candidate_pending_source_review
          generic names
          1. ZIFTOMENIB
          id
          ind-span-8b45bc2df3b3237265e6
          label id
          3213879b-dd88-413b-9910-8fd422c99805
          positive predicate support span
          end
          389
          end exclusive
          true
          exact text
          is a menin inhibitor indicated
          label id
          3213879b-dd88-413b-9910-8fd422c99805
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
          start
          359
          qualifier mentions
          1. context exact
            OMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) wi
            kind
            age
            polarity
            not_inferred
            span
            end
            425
            end exclusive
            true
            exact text
            adult patients
            label id
            3213879b-dd88-413b-9910-8fd422c99805
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
            start
            411
          2. context exact
            myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options.
            kind
            biomarker
            polarity
            not_inferred
            span
            end
            564
            end exclusive
            true
            exact text
            NPM1 ) mutation who have no satisfactory alt
            label id
            3213879b-dd88-413b-9910-8fd422c99805
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
            start
            520
          3. context exact
            nhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutatio
            kind
            stage_or_setting
            polarity
            not_inferred
            span
            end
            474
            end exclusive
            true
            exact text
            relapsed or refractory acute myeloid leukem
            label id
            3213879b-dd88-413b-9910-8fd422c99805
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
            start
            431
          4. context exact
            th a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options.
            kind
            prior_therapy_or_line
            polarity
            not_inferred
            span
            end
            590
            end exclusive
            true
            exact text
            no satisfactory alternative treatment options
            label id
            3213879b-dd88-413b-9910-8fd422c99805
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
            start
            545
          regulatory links
            schema version
            0.1.0
            source batch sha256
            fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
            source defined aliases
              source span
              end
              591
              end exclusive
              true
              exact text
              KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options.
              label id
              3213879b-dd88-413b-9910-8fd422c99805
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
              start
              350
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%223213879b-dd88-413b-9910-8fd422c99805%22
              spl effective date
              2025-12-09
              spl set id
              b650f696-3391-4274-8b55-a5f5e9d04769
              spl version
              1
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              tumor_directed_candidate
              Passage 3 · unclassified context
              application numbers
              1. NDA220305
              brand names
              1. Komzifti
              classification reasons
              1. no_unambiguous_positive_indication_predicate
              clinical review status
              pending
              content role
              unclassified_context
              context span
              end
              597
              end exclusive
              true
              exact text
              r the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 )
              label id
              3213879b-dd88-413b-9910-8fd422c99805
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
              start
              392
              current approval status
              not_reconciled
              duplicate text group
              dup-fff66ef52f5579fb2c0b
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. ZIFTOMENIB
              id
              ind-span-e7160aef5070ab3dc397
              label id
              3213879b-dd88-413b-9910-8fd422c99805
              positive predicate support span
              Source null
              qualifier mentions
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
                  source defined aliases
                    source span
                    end
                    597
                    end exclusive
                    true
                    exact text
                    ( 1 )
                    label id
                    3213879b-dd88-413b-9910-8fd422c99805
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    0031a917d502dc8fe4b83b4b61f50e532d41e968aebec30e055dbea806c23c9b
                    start
                    592
                    source url
                    https://api.fda.gov/drug/label.json?search=id%3A%223213879b-dd88-413b-9910-8fd422c99805%22
                    spl effective date
                    2025-12-09
                    spl set id
                    b650f696-3391-4274-8b55-a5f5e9d04769
                    spl version
                    1
                    structured fields status
                    not_extracted_no_values_inferred_from_mentions
                    structured indication
                    age
                    Source null
                    approval pathway
                    Source null
                    biomarker and test
                    Source null
                    disease stage
                    Source null
                    limitations
                    Source null
                    line
                    Source null
                    prior therapy
                    Source null
                    regimen
                    Source null
                    tumor histology
                    Source null
                    use intent
                    unclear

                    Preserved source evidence · Not medical advice